

**Date: March 29, 2025**

<b>BSE Limited</b> <b>Listing Department-</b> <b>Phiroze Jeejeebhoy Towers</b> <b>Dalal Street</b> <b>Mumbai- 400001</b> <b>Scrip Code: 544292, ISIN: INE013P01021</b>	<b>National Stock Exchange of India Ltd</b> <b>Exchange Plaza, C-1, Block G,</b> <b>Bandra Kurla Complex,</b> <b>Bandra (E)</b> <b>Mumbai – 400 051</b> <b>Symbol: ONESOURCE</b>
---	---

Dear Sir/ Madam,

Reg: **Disclosure under Reg 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations)**

Subject: **Completion of US-FDA Inspection at OneSource: Unit 2: Doddaballapura, Bangalore, a manufacturing Unit of the Company**

We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Unit 2 Facility of OneSource Specialty Pharma Limited, located at Doddaballapura, 3rd Phase, Industrial Area, Bangalore, from March 20, 2025, to March 28, 2025.

The inspection has concluded with four observations. The Company will respond to these observations comprehensively to FDA within the stipulated time frame.

We will keep the stock exchanges informed of any further developments in this matter.

Please take the above information on record.

For and on behalf of  
**OneSource Specialty Pharma Limited**

**Trisha A**  
Company Secretary and Compliance Officer  
Membership Number: A47635